Navigation Links
Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
Date:9/2/2008

Conference Call Scheduled for Today - Tuesday, September 2, 2008 at 5:00

p.m. Eastern Time

MOUNTAIN VIEW, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced positive results from its first Phase 3 clinical trial of AZ-004 (Staccato(R) loxapine) in schizophrenic patients with acute agitation. Both the 5 mg and 10 mg doses of AZ-004 met the primary endpoint of the trial, which was a statistically significant reduction in agitation from baseline to the 2-hour post-dose time point, compared to placebo. AZ-004 is an inhalation product candidate being developed for the treatment of acute agitation in patients with schizophrenia or bipolar disorder. AZ-004 is being developed through Symphony Allegro, a product development partnership formed between Alexza and Symphony Capital, LLC.

"Alexza initiated the first Phase 3 clinical trial of our lead program in late February and completed enrollment in less than four months, and today we are reporting positive top-line results for the primary and secondary endpoints," said James V. Cassella, PhD, Alexza Senior Vice President, Research and Development. "We believe that the ability to provide loxapine via our Staccato technology, thus combining a drug with a well-established mechanism of action with rapid absorption and patient self-administration, makes AZ-004 a potentially important new drug candidate for treating acute agitation."

"The clinical data we have seen to date, in terms of both efficacy and side-effect profiles, are compelling," said Michael H. Allen, MD, Director of Research, University of Colorado Depression Center. "There is a significant unmet medical need to treat acute agitation with ne
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
2. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
3. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
4. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
5. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
6. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
7. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
8. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
9. Calabar AB Today Announced New Financing for Continuation of the Phase II Program in Patients With Dry Mouth
10. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
11. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , Sept. 4, 2015  PTC Therapeutics, ... announce five recipients of its first-ever global awards ... Vision and Empowerment), designed to aid nonprofit organizations ... dystrophy (DMD) community. The announcement is made as ... World Duchenne Awareness Day on Monday, September 7, ...
(Date:9/4/2015)... , September 4, 2015 ... ), a clinical-stage pharmaceutical company focused on the development ... Company will participate in the upcoming Rodman & Renshaw ... September 8-10, 2015 in New York City ... Oramed, will present a corporate overview on September 9, ...
(Date:9/4/2015)... , September 4, 2015 Future ... Allergic Rhinitis drugs - new ... Where is the market for allergic rhinitis drugs ... Visiongain ,s new report shows you potential revenues ... prospects. Our 326 page report provides 273 ...
Breaking Medicine Technology:PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 2PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 3PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 4Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7
... Globus Medical, Inc., the largest,privately held spinal ... in motion preservation technology, today announced the completion ... study. The,SECURE(R)-C device is designed to mimic the ... pain and restore function as an alternative to ...
... Siemens Healthcare and,Laboratory Corporation of America(R) Holdings ... non-exclusive agreement to discuss future,possibilities to co-develop ... of,companion diagnostics, metabolic syndrome, oncology and diabetes. ... developing new tests that,could make the biggest ...
Cached Medicine Technology:Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4
(Date:9/4/2015)... , ... September 04, 2015 , ... Many consumers are looking for a quick and ... their solution. , The patent-pending K Med Cups provide a quick and simple way to ... relieve a cold, flu or cough. As a result, they enhance comfort and health. The ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... Having access ... This has led to an increasing amount of unnecessary emergency room visits which affects ... and taxes the country’s health bill. Fortunately, a solution to alleviate this problem has ...
(Date:9/4/2015)... ... September 04, 2015 , ... Compliance ... to settlements under the Stark physician self-referral law. “Stark Law DOs and ... from Atlantic Information Services, Inc. (AIS), will detail which deals are attracting the ...
(Date:9/4/2015)... IL (PRWEB) , ... September 04, 2015 , ... Friday ... Geneva, IL hosting Generation Rescue’s A Night of Hope event supporting families affected by ... French and Rowena and Joe Salas, joined together at the Oscar Swan Inn to ...
(Date:9/3/2015)... ... September 03, 2015 , ... TransPack Toon gives users a set of ... wipes and framing transitions in 30 different styles. Presets range from snow, underwater, forest, ... X. , TransPack Toon features 90 cartoon transitions from 30 unique styles. Editors ...
Breaking Medicine News(10 mins):Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2Health News:Jenny McCarthy & Donnie Wahlberg Help Raise Over $200,000 For Generation Rescue’s ‘Night Of Hope’ Chicago Charity Event 2Health News:Pixel Film Studios Releases TransPack Toon, a New FCPX Transition 2
... , A nano-sensor for better detection of Mad Cow ... advance in food safety, researchers in New York are ... low levels of the deadly prion proteins that cause ... sensor, which detects binding of prion proteins by detecting ...
... JOSE, Calif., March 3 Interwoven, Inc.,(Nasdaq: ... solutions, today,announced that it will present a joint ... the 2008 AIIM International Exposition and Conference,on March ... & Exhibition Center., (Logo: http://www.newscom.com/cgi-bin/prnh/20071205/INTWOVLOGO ), ...
... The Quigley,Corporation (Nasdaq: QGLY ) today reported net ... 31, 2007, compared to $14.2 million,reported for the same ... 2007,net sales were $39.5 million compared to $42.1 million ... quarter ended December 31, 2007 reflects a net sales,decrease ...
... to treat their diabetes ... and out, PRINCETON, N.J., March 3 Novo Nordisk, a,world ... program is back for a third year of providing free diabetes,education ... by,diabetes. This dynamic outreach kicks off in New York City, where ...
... Will Conduct, Webcast For Pet Owners, Covering ... March 3 Morris Animal Foundation (MAF) will,sponsor a ... their pets on,March 13, 2008, from 8:00 p.m. to ... all aspects of pain management, including common,causes of pain, ...
... Beauty Get a New Jolt with Java, ... destination that helps solve people,s everyday problems by,providing ... the,world,s most popular bean by providing interesting facts ... Awareness Month" in March.,HowToDoThings.com has created a Caffeine ...
Cached Medicine News:Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 2Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 3Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 4Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 5Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 6Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 7Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 8Health News:American Chemical Society's weekly PressPac -- Feb. 27, 2008 9Health News:Blue Cross Blue Shield of Massachusetts and Interwoven to Present at 2008 AIIM International Exposition and Conference 2Health News:The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007 2Health News:The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007 3Health News:The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007 4Health News:The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007 5Health News:The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007 6Health News:The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007 7Health News:The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007 8Health News:Video: DIVABETIC - Makeover Your Diabetes Kicks Off 2008 Events 2Health News:Video: DIVABETIC - Makeover Your Diabetes Kicks Off 2008 Events 3Health News:Video: DIVABETIC - Makeover Your Diabetes Kicks Off 2008 Events 4Health News:Pain Management For Your Pets, Key Information Every Pet Owner Should Know - Live Webcast to Pet Owners, March 13, 8:00 p.m. to 9:00 p.m. (EDT) Via Morris Animal Foundation 2Health News:HowToDoThings.com Brews Up New Uses for Coffee That Will Perk You Up in Recognition of March's 'Caffeine Awareness Month' 2
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: